
    
      Females who meet the inclusion criteria will receive breast ultrasonography, mammography and
      pathological examinations by core needle biopsy. All participants will receive a follow-up at
      an 6-month interval for 2 years. During the follow-up period, whether the symptoms relieve
      will be evaluated.
    
  